Given the ability of ZEB1 silencing to drive transcriptional changes with evidence of epigenetic reprogramming, we next investigated the clinical relevance of the associated DNAme changes for these 26 genes across clinical breast cancer tumor samples. This evidence concerns the gene ZEB1 and neoplasm.